Novartis gets final EC nod for Votubia

Novartis ($NVS) has won European approval for Votubia as a treatment for a rare type of brain tumor known as subependymal giant cell astrocytoma associated with tuberous sclerosis complex. With the same active ingredient as the kidney cancer drug Afinitor, Votubia is the first drug approved for these tumors. Release | Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…